To the Editor: Dr Lasser and colleagues1 found that 10.2% of all new drugs approved between
1975 and 1999 either acquired a black box warning or were withdrawn. Thus,
they conclude that postapproval adverse drug reactions (ADRs) are common.
I would like to address 2 additional issues in postmarketing surveillance.
First, premarketing clinical trials are consistently designed with a
narrow spectrum of clinical disorders and participating patient profiles to
achieve a required statistical result. Rarely do these patients reflect the
exact clinical profiles, including use of concomitant medications, of the
patient population to whom the drugs will be administered after marketing.
Second, serious ADRs are often rare, albeit extremely important. Therefore,
the number of patient exposures required to identify such events may be large,
sometimes numbering in the millions. If only a fraction of such events is
reported to either the manufacturer or the Food and Drug Administration (FDA),
that number becomes enormous.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.